Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

Status: Recruiting
Location: See all (15) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this clinical study is to collect safety and efficacy data of the VDyne System to support Conformitè Europëenne (CE) Mark of the VDyne System.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Severe or greater tricuspid valve regurgitation of primary or secondary etiology.

• NYHA class ≥ II. If NYHA Class IV, patient must be ambulatory.

• Subject is adequately treated with medical therapy for heart failure \>30 days prior to index procedure, including a diuretic.

• Heart Team determines patient is a recommended candidate for the VDyne System.

• Age 18 years or older at time of the index procedure.

• Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for treatment with the VDyne System.

Locations
Other Locations
Australia
Flinders Medical Centre
RECRUITING
Adelaide
Princess Alexandra Hospital
RECRUITING
Brisbane
The Prince Charles Hospital
RECRUITING
Brisbane
Monash Heart
RECRUITING
Melbourne
St. Vincent Hospital
RECRUITING
Sydney
Austria
Johannes Kepler University Linz - JKU
RECRUITING
Linz
Universitätsklinik für Herzchirurgie Medizinische Universität Wien
RECRUITING
Vienna
Belgium
AZ Sint Jan Hospital
RECRUITING
Bruges
Germany
Herz & Diabeteszentrum Nordrhein Westfalen
RECRUITING
Bad Oeynhausen
Vivantes Klinik Am Urban
RECRUITING
Berlin
Universitätsklinikum Schleswig-Holstein, Campus Kiel
RECRUITING
Kiel
Universitätsmedizin Rostock
RECRUITING
Rostock
New Zealand
Waikato Hospital
RECRUITING
Hamilton
Spain
Hospital Clínico San Carlos
RECRUITING
Madrid
Hospital Universitario Puerta de Hierro
RECRUITING
Madrid
Contact Information
Primary
Laura Moffett
lmoffett@vdyne.com
+1.952.303.2821
Backup
Pree Bassi
pbassi@vdyne.com
+1-612-438-6888
Time Frame
Start Date: 2023-03-01
Estimated Completion Date: 2029-09-30
Participants
Target number of participants: 120
Treatments
Experimental: VDyne System Treatment Arm
Related Therapeutic Areas
Sponsors
Leads: VDyne, Inc.

This content was sourced from clinicaltrials.gov